Schrodinger, Inc. · NASDAQ:SDGR
Schrodinger — Investor Presentation (November 2025)
33 slides from Schrodinger's investor presentation, Nov 5, 2025
Slide 1: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery November 2025
Slide 2: Cautionary Note and Disclaimer
Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, made by Schröding
Slide 3: Pioneering Digital Chemistry
30+ years of innovation Pioneering ~800 employees worldwide; >40% Ph.D. Digital >50% of employees dedicated to R&D Chemistry ~1,752 customers, including top 20 innovative biopharma1 Portfolio of 25+ collaborative and internal programs 1 As measured by revenue. 3
Slide 4: Our Target-to-Clinic Digital Chemistry Laboratory
Our Target-to-Clinic Digital Chemistry Laboratory Target Hit Lead Preclinical Validation Identification Optimization Development Protein structure Large-scale virtual Compound Polymorph prediction determination screening enumeration Drug formulation Druggability Fragment screening In silico assays f
Slide 5: Multi-Pronged Business Enabled by Highly Differentiated Computational Platform
Multi-Pronged Business Enabled by Highly Differentiated Computational Platform SOFTWARE LICENSING • Life Sciences COLLABORATIONS • Materials Design • Drug Design INTERNAL PORTFOLIO ~1,752 customers worldwide1 • Materials Design 19 drug discovery collaborators2 • Drug Discovery & Development 7+ activ
Slide 6: Our Computational Platform
Our Computational Platform 6
Slide 7: Designing Drugs Is a Highly Challenging Multi-Parameter Optimization Problem
Designing Drugs Is a Highly Challenging Multi-Parameter Optimization Problem Need to identify a molecule that balances many … anti-correlated properties: Potency ✓ ✕ ✓ ✕ ✓ ✓ 33% success Selectivity ✕ ✓ ✓ ✓ ✕ ✓ IND Solubility ✕ ✕ ✕ ✓ ✓ ✕ delivery Bioavailability ✕ ✕ ✕ ✕ ✕ ✕ 66% Clearance / Half-life
Slide 8: Schrödinger’s Vision for the Future of Drug Discovery
Schrödinger’s Vision for the Future of Drug Discovery If all properties can be calculated with perfect accuracy, designing drugs would have a much higher success rate, be much faster and cheaper, and would produce much higher-quality molecules. Select THE best molecule “All” synthesizable molecules
Slide 9: Digital Chemistry Laboratory Leverages Physics + AI
Digital Chemistry Laboratory Leverages Physics + AI Physics + AI/ML Physics-based Training Set for AI/ML Artificial Intelligence / Methods Generated Using Physics Machine Learning ✓ No training set required ✓ Fast ✓ Effective at interpolation ✓ Can extrapolate into novel ✓ Accurate ✓ Fast chemical s
Slide 10: Physics-Enabled AI/ML Platform
Physics-Enabled AI/ML Platform PHYSICS + AI PHYSICS + AI PHYSICS MACHINE MAKE & ADVANCE PHYSICS generates generates determines LEARNING TEST BEST computes protein/ligand 1,000,000,000s properties of subset scores 10s of MOLECULE properties of top structures of molecules of molecules 1,000,000,000s m
Slide 11: Advancing the Platform in 2025
Advancing the Platform in 2025 Continuing to Integrate Physics & AI/ML Target Hit Lead Preclinical Validation Discovery Optimization Development High Resolution Protein Biologics Informatics Formulation & Crystal Structure Prediction Structure Prediction AI/ML Integration in Informatics Platform Vir
Slide 12: Our Therapeutics Pipeline
Our Therapeutics Pipeline 12
Slide 13: Platform Validated by Clinical Success
Platform Validated by Clinical Success(1)(2) Phase 1 Phase 2 Phase 3 FDA-Approved TIBSOVO4 Immuno-oncology Metabolic Diseases3 Psoriasis3 IDHIFA4 Myelofibrosis Inflammatory Bowel Disease5 Hematologic Malignancies Obesity Solid Tumors Additional programs in discovery and preclinical development with:
Slide 14: Clinical Programs with Breakthrough Potential
Clinical Programs with Breakthrough Potential SGR-1505 SGR-3515 (MALT1) (Wee1/Myt1) • Phase 1 ongoing in patients • Phase 1 ongoing in patients with advanced R/R B-cell with advanced solid tumors malignancies • Initial data expected 1H 2026 • Encouraging initial Phase 1 data presented in June 2025 1
Slide 15: MALT1 Protease Inhibition Clinically Validated
MALT1 Protease Inhibition Clinically Validated Allosteric Inhibition of MALT1 Non-Hodgkin's Lymphoma (NHL) • Clinically validated by 3rd party MALT1 28% ORR* monotherapy1,3,4 inhibitor showed monotherapy and Chronic Lymphocytic Leukemia (CLL/SLL) combination activity in human B-cell 67% ORR in BTK*
Slide 16: Summary Phase 1 Clinical Study
Summary Phase 1 Clinical Study Initial Data at EHA • SGR-1505 observed to be well-tolerated with a favorable safety profile • Strong target engagement • Encouraging preliminary efficacy across range of B-cell histologies – Monotherapy signal in chronic lymphocytic leukemia (CLL) and Waldenström macr
Slide 17: SGR-1505 Observed to Have a Favorable Safety Profile and Was Well-Tolerated
SGR-1505 Observed to Have a Favorable Safety Profile and Was Well-Tolerated TEAE TRAE • 43% of patients experienced ≥1 treatment-related adverse event Common (≥10%) Any grade Grade ≥3 Any grade Grade ≥3 (n, %) (n, %) (n, %) (n, %) (TRAE) TEAE/TRAEs • Well tolerated with no dose limiting Any TEAE 42
Slide 18: IL-2 Response at Steady State Confirms Inhibition of NF-κB Signaling
IL-2 Response at Steady State Confirms Inhibition of NF-κB Signaling IL-2 inhibition through C2 D1 (steady state) by dose groups • SGR-1505 inhibits T-cell derived IL-2 upon ex vivo stimulation – ~90% inhibition in the majority of PD-evaluable patients treated at ≥150 mg QD and all Q12H doses at ste
Slide 19: Encouraging Preliminary Efficacy Across Range of B-Cell Malignancies
Encouraging Preliminary Efficacy Across Range of B-Cell Malignancies CLL/SLL MZL WM GCB-DLBCL, DLBCL NOS, FL, Non-GCB Dose (mg) (n=16) (n=5) (n=5) MCL, PMBCL, THRLBCL (n=11) DLBCL (n=3) QD Q12H 350 50 50 3L 100 75 150 100 7L 200 125 2L 300 150 9L 6L 9L 3L 50 Treatment Ongoing 2L Exposed to BTKi Best
Slide 20: Phase 1 Summary and Next Steps
Phase 1 Summary and Next Steps Key Study Findings • SGR-1505 observed to be well-tolerated with a favorable safety profile • Strong target engagement • Encouraging preliminary efficacy across range of B-cell histologies – Monotherapy signal in CLL and WM Study Status and Next Steps • Complete Phase
Slide 21: Wee1 Inhibition Clinically Validated in 3rd Party Studies
Wee1 Inhibition Clinically Validated in 3rd Party Studies Head and Neck Cancer Breast Cancer 50% ORR (chemo combination)7 SGR-3515 Combines 26% ORR (cisplatin combination)1 Schrödinger Wee1/Myt1 Wee1 Inhibitor SchrödingerActivity Wee1 Inhibitor Lung Cancer Program •Program Objectives Objectives Oppo
Slide 22: SGR-3515 Status and Next Steps
SGR-3515 Status and Next Steps Strong mechanistic • Clinically validated target rationale • Potential benefit in wide range of tumor types • Potentially superior Wee1/Myt1 potency, improved selectivity and lower drug-drug interaction liability in preclinical models Differentiated profile • Profile e
Slide 23: Financial Overview
Financial Overview @ Schrédinger
Slide 24: 3Q25 Financial Highlights vs. 3Q24
3Q25 Financial Highlights vs. 3Q24 Three Months Ended September 30 3Q 2024 3Q 2025 % Change Software revenue $31.9 $40.9 28% Drug discovery revenue $3.4 $13.5 295% Total revenue $35.3 $54.3 54% Gross profit $17.7 $28.0 Software gross margin 73% 73% Operating expenses $86.2 $74.0 (14%) Other income $
Slide 25: Four-Quarter Trailing Average Software Quarterly Revenue Trend
Four-Quarter Trailing Average Software Quarterly Revenue Trend 52.5 50.2 50 48.9 45.1 42.3 39.8 40.1 41.6 40 33.9 33.7 33.5 34.6 30.0 31.5 31.6 30 28.3 $ Millions 24.6 24.9 23.1 23.8 21.3 19.6 20 18.0 10 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2020 2020 2020 2021
Slide 26: Full Year 2024 Key Performance Indicators (KPIs)
Full Year 2024 Key Performance Indicators (KPIs) Software KPI 2023 2024 Total annual contract value (ACV) $154.2M $190.8M ACV of Top 10 Customers $51.0M $73.1M Number of customers with ACV ≥$5M 4 8 Number of customers with ACV ≥$1M 27 31 Number of customers with ACV ≥$500k 54 61 Number of customers
Slide 27: Growth in Top 20 Customer Average ACV By Customer Ranking Group Over Time
Growth in Top 20 Customer Average ACV By Customer Ranking Group Over Time *Represents the average ACV per customer for the top 5, 10, 15 and 20 customers for each year. This figure represents the growth in ACV by each group but does not represent the growth of any individual customer or customers as
Slide 28: Software and Drug Discovery Revenues: 2019-2024
Software and Drug Discovery Revenues: 2019-2024 250 Software products and services Drug discovery Drug discovery 200 $58 $27 2019-24 CAGR 7.6% Revenue ($millions) $45 150 $25 100 $16 $180 $159 $19 $136 $113 Software $50 $93 $67 2019-24 CAGR 22.0% $0 2019 2020 2021 2022 2023 2024 Cash is supplemented
Slide 29: Capital Allocation Strategy Built on Proprietary Insights and Competitive Advantages
Capital Allocation Strategy Built on Proprietary Insights and Competitive Advantages in Computational Chemistry Aiming to Generate Positive Returns from Deployment of Technology, Expertise and Capital Opportunities that leverage: Commercially Validated Target or Useful Development Goal Innovation •
Slide 30: 2025 Financial Guidance
2025 Financial Guidance (As of November 5, 2025) 2024 Actual 2025 Guidance Software revenue $180.4M +8% – 13% Drug discovery revenue $27.2M $49M – $52M Software gross margin 80% 73% – 75% Operating expenses $341.4M Lower than 2024 Significantly lower Cash used in operating activities $157.4M than 20
Slide 31: Strategic Priorities
Strategic Priorities • Complete Phase 1 dose escalation studies for SGR-1505 and SGR-3515 • Present initial Phase 1 clinical data for SGR-3515 in 1H26 • Increase customer adoption of computational platform • Deliver planned major enhancements to the platform • Advance therapeutics portfolio for part
Slide 32: Revolutionizing Medicines and Materials Discovery
Revolutionizing Medicines and Materials Discovery November 2025
Slide 33: Appendix
Appendix Annual Contract Value (ACV). With respect to contracts that have a duration of one year or less, or contracts of more than one year in duration that are billed annually, ACV is defined as the contract value billed during the applicable period. For contracts with a duration of more than one